DEFA14A: Vaxart Urges Stockholders to Back Reverse Split for Nasdaq Relisting

Vaxart's CEO urges stockholders to approve a reverse stock split to regain Nasdaq listing, citing benefits for investor access and financing, despite a recent Stop Work Order on its COVID-19 vaccine trial.

Summary

• Vaxart's CEO, Steven Lo, is urging stockholders to vote FOR a reverse stock split proposal by September 4, 2025, to facilitate relisting on Nasdaq.
• Relisting on Nasdaq is deemed a strategic imperative to maximize long-term value, offering broader investor access, greater visibility, enhanced financial flexibility, improved market perception, and stronger partnership positioning.
• The reverse stock split proposal includes a significantly narrower split ratio and a proportionally reduced authorized share count to minimize dilution, and will apply equally to all common equity, including option holdings and future grants.
• The company has appealed Nasdaq's suspension and is scheduled to meet with their hearings panel on August 14, 2025, believing relisting is contingent on the reverse stock split.
• Scientific progress includes rapid enrollment in the COVID-19 oral vaccine Phase 2b trial (approximately 5,000 of 10,000 participants) before a Stop Work Order was received, with topline data anticipated in late 2026.
• Positive Phase 1 results were announced for the second-generation Norovirus vaccine, showing stronger antibody responses and excellent safety, with Phase 2 partnership discussions ongoing.
• A preclinical Avian Influenza candidate demonstrated 100% protection in a robust ferret challenge model, with full results pending publication.
• Vaxart has extended its cash runway into 2026 through cost reductions while preserving its ability to deliver multiple data readouts.

Sentiment

Score: 4

Explanation: The filing presents a mixed bag. While there's positive scientific progress in other programs and a clear strategy to regain Nasdaq listing, the immediate necessity of a reverse stock split due to low share price and the significant 'Stop Work Order' on the lead COVID-19 program are substantial negatives. The overall sentiment is cautious, leaning negative due to the operational setback and the underlying issue of delisting.

Positives

• Positive Phase 1 results for the second-generation Norovirus vaccine, showing stronger antibody responses and excellent safety.
• Preclinical Avian Influenza candidate demonstrated 100% protection in a robust ferret challenge model.
• Rapid enrollment in the COVID-19 oral vaccine Phase 2b trial, with over 5,000 participants enrolled, expected to provide comprehensive data.
• Extension of cash runway into 2026 through cost reductions, preserving ability for multiple data readouts.
• The proposed reverse stock split includes a narrower ratio and reduced authorized share count to minimize dilution.

Negatives

• The company received a "Stop Work Order" for its COVID-19 oral vaccine Phase 2b trial, requiring determination of next steps.
• Current share price has remained below the Nasdaq minimum bid price, leading to Nasdaq suspension and the need for a reverse stock split.
• Frustration among stockholders regarding the current share price and skepticism about another reverse stock split proposal.
• Reliance on multiple funding sources is necessary due to events like the Stop Work Order, highlighting the capital intensity of drug development.

Risks

• Failure to regain Nasdaq listing could limit access to institutional investors, reduce visibility, hinder financing on favorable terms, and negatively impact market perception and partnership positioning.
• The "Stop Work Order" on the COVID-19 oral vaccine Phase 2b trial introduces uncertainty regarding the study's progression and future.
• Drug development is capital intensive, and the company must rely on multiple funding sources, which could lead to dilution if financing terms are unfavorable.
• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors, including those described in the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q.

Future Outlook

Vaxart anticipates that regaining its Nasdaq listing will provide critical advantages, including broader investor access, enhanced financial flexibility, and stronger partnership positioning, which are essential for advancing its product pipeline. The company expects topline data for its COVID-19 oral vaccine Phase 2b trial in late 2026 and is pursuing a Phase 2 partnership for its Norovirus vaccine. Management aims to continue advancing transformative oral vaccines to improve global health.

Management Comments

• "We deeply appreciate your continued support and commitment to Vaxart's mission."
• "We understand that some stockholders—particularly those who have been with us for years—may feel frustrated by the current share price and are skeptical about another reverse stock split proposal. We hear you and we share that frustration."
• "Relisting on Nasdaq is a strategic imperative for Vaxart's future and will ultimately maximize long-term value for all stockholders."
• "We recognize that reverse stock splits are often met with concern, especially among retail investors. Let us be clear: we do not take this decision lightly."
• "Given our current valuation and absent substantial near-term appreciation, a reverse stock split remains the most viable path to relist on Nasdaq."
• "While we deem re-listing on Nasdaq essential to Vaxart's market position, our core mission remains unchanged: to advance transformative oral vaccines that improve global health."
• "We remain committed to transparency, scientific excellence, and creating long-term value for all stockholders—retail and institutional alike."

Industry Context

The biotechnology industry, particularly vaccine development, is highly capital-intensive and relies heavily on investor confidence and access to capital markets. A Nasdaq listing is crucial for biotech companies to attract institutional investment, gain analyst coverage, and secure partnerships, which are vital for funding lengthy and expensive clinical trials. Vaxart's efforts to relist on Nasdaq reflect a common challenge for smaller biotech firms to maintain market visibility and financial flexibility amidst intense competition and regulatory hurdles, such as the 'Stop Work Order' which can significantly impact development timelines and investor sentiment.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Directly impacted by the proposed reverse stock split, which aims to improve share price and liquidity but may cause frustration. Potential for increased value if Nasdaq relisting is successful.
• Employees/Management/Directors: The reverse stock split will be consistently applied to all common equity, including option holdings and future grants, aligning their interests with stockholders.
• Investors (Institutional/Retail): Nasdaq relisting aims to provide broader access, greater visibility, and enhanced liquidity.
• Partners: Nasdaq listing provides credibility and leverage in negotiations, enhancing partnership positioning.
• Government Partners (e.g., BARDA): The "Stop Work Order" and need for multiple funding sources highlight the dynamic nature of these relationships.

Next Steps

• Stockholders to vote on the reverse stock split proposal by September 4, 2025.
• Special Meeting of Stockholders on September 5, 2025.
• Meeting with Nasdaq hearings panel on August 14, 2025, regarding the appeal of suspension.
• Stockholder Fireside Chat on August 20, 2025, at 4:30 p.m. ET.
• Determine next steps for the COVID-19 oral vaccine Phase 2b study following the Stop Work Order.
• Continue discussions for a Phase 2 partnership for the Norovirus vaccine.
• Publish full results for the Avian Influenza candidate upon completion of analysis.
• Continue efforts to advance transformative oral vaccines.

Key Dates

Recommendation

While Vaxart is pursuing a critical strategic move to relist on Nasdaq, which could improve long-term investor access and financing, the immediate necessity of a reverse stock split due to sustained low share price and the significant 'Stop Work Order' on its lead COVID-19 vaccine program introduce considerable uncertainty and risk. The scientific progress in other programs (Norovirus, Avian Influenza) offers some upside, but the operational setback on the COVID-19 trial is a major concern. An investor should hold to observe the outcome of the Nasdaq relisting vote, the appeal process, and the resolution of the Stop Work Order before making further investment decisions, as the near-term outlook is highly dependent on these events.

Keywords

Vaxart, VXRT, Reverse Stock Split, Nasdaq Relisting, Oral Vaccines, Biotechnology, COVID-19 Vaccine, Norovirus Vaccine, Avian Influenza Vaccine, Clinical Trials, SEC Filing, Biotech, Pharmaceuticals